The αTSR Domain of Plasmodium Circumsporozoite Protein Bound Heparan Sulfates and Elicited High Titers of Sporozoite Binding Antibody After Displayed by Nanoparticles

Ming Xia, Frank Vago, Ling Han, Pengwei Huang, Linh Nguyen, Geert-Jan Boons, John S Klassen, Wen Jiang, Ming Tan*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

INTRODUCTION: Malaria is a devastating infectious illness caused by protozoan Plasmodium parasites. The circumsporozoite protein (CSP) on Plasmodium sporozoites binds heparan sulfate proteoglycan (HSPG) receptors for liver invasion, a critical step for prophylactic and therapeutic interventions.

METHODS: In this study, we characterized the αTSR domain that covers region III and the thrombospondin type-I repeat (TSR) of the CSP using various biochemical, glycobiological, bioengineering, and immunological approaches.

RESULTS: We found for the first time that the αTSR bound heparan sulfate (HS) glycans through support by a fused protein, indicating that the αTSR is a key functional domain and thus a vaccine target. When the αTSR was fused to the S domain of norovirus VP1, the fusion protein self-assembled into uniform S 60-αTSR nanoparticles. Three-dimensional structure reconstruction revealed that each nanoparticle consists of an S 60 nanoparticle core and 60 surface displayed αTSR antigens. The nanoparticle displayed αTSRs retained the binding function to HS glycans, indicating that they maintained authentic conformations. Both tagged and tag-free S 60-αTSR nanoparticles were produced via the Escherichia coli system at high yield by scalable approaches. They are highly immunogenic in mice, eliciting high titers of αTSR-specific antibody that bound specifically to the CSPs of Plasmodium falciparum sporozoites at high titer.

DISCUSSION AND CONCLUSION: Our data demonstrated that the αTSR is an important functional domain of the CSP. The S 60-αTSR nanoparticle displaying multiple αTSR antigens is a promising vaccine candidate potentially against attachment and infection of Plasmodium parasites.

Original languageEnglish
Pages (from-to)3087-3107
Number of pages21
JournalInternational Journal of Nanomedicine
Volume18
DOIs
Publication statusPublished - 8 Jun 2023

Bibliographical note

Publisher Copyright:
© 2023 Xia et al.

Funding

The research described in this study was supported by the National Institute of Allergy and Infectious Diseases (NIAID, R56 AI148426-01A1 to M.T.), Cincinnati Children’s Hospital Medical Center (CCHMC, Innovation Funds 2018-2020, GAP Fund 2020-2021, and Research Innovation and Pilot Grant 2020-2021 to M.T.), and the Center for Clinical and Translational Science and Training (CCTST) of the University of Cincinnati College of Medicine (Pilot Collaborative Studies Grant 2018-2019 to M.T.) that was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR001425).

FundersFunder number
CCTST
Center for Clinical and Translational Science and Training
National Institutes of HealthUL1TR001425
National Institute of Allergy and Infectious DiseasesR56 AI148426-01A1
National Center for Advancing Translational Sciences
Cincinnati Children's Hospital Medical Center2020-2021
College of Medicine, University of Cincinnati2018-2019

    Keywords

    • Plasmodium
    • S nanoparticle
    • malaria
    • malaria vaccine
    • norovirus
    • receptor binding domain
    • αTSR domain

    Fingerprint

    Dive into the research topics of 'The αTSR Domain of Plasmodium Circumsporozoite Protein Bound Heparan Sulfates and Elicited High Titers of Sporozoite Binding Antibody After Displayed by Nanoparticles'. Together they form a unique fingerprint.

    Cite this